Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
The use of rituximab (RTX), an anti-CD20 monoclonal antibody (Ab), in refractory myasthenia gravis (MG) is associated with a better response in patients with Abs to the muscle-specific tyrosine kinase (MuSK) than in other MG subgroups. Anti-MuSK Abs are mostly IgG4 with proven pathogenicity and posi...
Main Authors: | Mariapaola Marino, Umberto Basile, Gregorio Spagni, Cecilia Napodano, Raffaele Iorio, Francesca Gulli, Laura Todi, Carlo Provenzano, Emanuela Bartoccioni, Amelia Evoli |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00613/full |
Similar Items
-
Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
by: Amber Eker, et al.
Published: (2020-08-01) -
Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis
by: Umberto Basile, et al.
Published: (2021-08-01) -
Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
by: Yung-Chuan Huang, et al.
Published: (2008-07-01) -
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients
by: Umberto Basile, et al.
Published: (2018-01-01) -
MuSK Antibody(+) Versus AChR Antibody(+) Myasthenia Gravis : Clinical, Neurophysiological and Morphological Aspects
by: Rostedt Punga, Anna
Published: (2007)